1. Home
  2. DRIO vs LUNG Comparison

DRIO vs LUNG Comparison

Compare DRIO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DarioHealth Corp.

DRIO

DarioHealth Corp.

N/A

Current Price

$6.81

Market Cap

53.2M

Sector

Health Care

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.45

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRIO
LUNG
Founded
2011
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.2M
57.9M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
DRIO
LUNG
Price
$6.81
$1.45
Analyst Decision
Strong Buy
Buy
Analyst Count
2
7
Target Price
$35.00
$5.38
AVG Volume (30 Days)
12.7K
590.9K
Earning Date
05-14-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
1559.02
7.64
EPS
1.25
N/A
Revenue
$7,394,000.00
$90,497,000.00
Revenue This Year
$20.27
$2.48
Revenue Next Year
$47.58
$18.46
P/E Ratio
$5.60
N/A
Revenue Growth
43.02
8.01
52 Week Low
$0.38
$1.13
52 Week High
$17.74
$3.88

Technical Indicators

Market Signals
Indicator
DRIO
LUNG
Relative Strength Index (RSI) 48.65 54.33
Support Level $6.13 $1.39
Resistance Level $9.24 $1.67
Average True Range (ATR) 0.58 0.12
MACD 0.09 0.02
Stochastic Oscillator 53.61 75.00

Price Performance

Historical Comparison
DRIO
LUNG

About DRIO DarioHealth Corp.

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: